Defective expression of high affinity IL-2 receptors on activated T cells from aged humans

International Immunology

Volumn 2, Issue 3, 1990, Pages 239-246

  Schwab, Risë ^a,b   Pfeffer, Lawrence M ^a,b   Szabo, Paul ^a,b   Gamble, David ^a,b   Schnurr, Christine M ^a,b   Weksler, Marc E ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Aging; IL 2 receptor; T cells

Indexed keywords

INTERLEUKIN 2 RECEPTOR;

ADULT; AGE; AGED; ARTICLE; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; AGING; COMPARATIVE STUDY; HUMAN; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MIDDLE AGE; MITOGENS; RECEPTORS, INTERLEUKIN-2; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES;

EID: 0025271565     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/2.3.239     Document Type: Article

References (36)

1. Gillis, S., Kozak, R, Durante, M, and Weksler, M E. 1981. Immunologic studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans. J. Clin. Invest. 67:937.
2. Schwab, R, Hausman, P B., Rinnooy-Kan, E A, and Weksler, M. E. 1985. Imunological studies of aging X. Impaired T lymphocytes and normal monocyte response from elderly humans to the mitogemc antibodies OKT3 and Leu4. Immunology 55:677.
3. VanWauwe, J. P., DeMey, J. R., and Goosens, J. G. 1980. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J. Immunol 124:2708.
4. VanWauwe, J. P. and Goosens, J. G. 1981. Mitogenic actions of Orthoclone OKT3 on human peripheral blood lymphocytes, effects of monocytes and serum components. Int J. Immunopharmacol. 3:203.
5. Schwab, R., Crow, M. K., Russo, C, and Weksler, M. E. 1985. Requirements for T cell activation by OKT3 monoclonal antibody, role of modulation of T3 molecules and Interleukin 1. J Immunol. 135:1714.
6. Robb, R. J., Greene, W. C., and Rusk, C. M. 1984. Low and high affinity cellular receptors for interleukin 2. implications for the level of Tac antigens. J Exp. Med 160:1126.
7. Robb, R. J., Munck, A, and Smith, K. A. 1981. T cell growth factor receptors: quantification, specificity and biological relevance. J. Exp. Med. 154:1455.
8. Sharon, M., Klausner, R. D, Cullen, B R, Chizzonite, R, and Leonard, W J. 1986. Novel IL-2 receptor subunit detected by cross-linking under high affinity conditions. Science 234:859.
9. Tsudo, M, Kozak, R. W., Goldman, C K., and Waldmann, T. A. 1986. Demonstration of a non-Tac peptide that binds interleukin-2: a potential participant in a multichain interleukin 2 receptor complex. Proc. Natl Acad Sci. USA 83:9695.
10. Teshigawara, K, Wang, H.-M, Kato, K., and Smith, K. A. 1987. Interleukin 2 high affinity receptor expression requires two distinct binding proteins. J. Exp. Med. 165:223.
11. Robb, R. J, Rusk, C M., Yodoi, J., and Greene, W. C. 1987. An interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high affinity receptors. Proc. Natl. Acad. Sci. USA 84:2002.
12. Dukovich, M., Wano, Y., Thuy, L. T. B, Katz, P., Cullen, B R., Kerhl, J. H, and Greene, W C. 1987. Identification of a second human interleukin-2 binding protein and its role in the assembly of the high affinity IL-2 receptor. Nature 327:518.
13. Uchiyama, T., Broder, S., and Waldmann, T. A. 1981. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. J Immunol 126:1393.
14. Robb, R. J. and Greene, W. C. 1983. Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen. J. Exp. Med 158:1332.
15. Leonard, W. J., Depper, J. M, Robb, R J, Waldmann, T A., and Greene, W C. 1983. Characterization of the human receptor for T-cell growth factor. Proc. Natl. Acad Sci USA 80:6957.
16. Gillis, S. and Smith, K A. 1977. In vitro generation of tumor-specific cytotoxic lymphocytes Secondary allogenetc mixed tumor lymphocyte culture of normal murine spleen cells. J Exp Med. 146:468.
17. Jordan, G W. 1972. Basis for the probt analysis of an interferon plaque reduction assay. J. Gen. Virol 14:49.
18. Pfeffer, L. M., Donner, D. B., and Tamm, I. 1987. Interferon-aJpha down-regulates insulin receptors in lymphoblastoid (Daudi) cells Relationship to inhibition of cell proliferation. J Biol Chem. 252:3665.
19. Szabo, P., Campana, T., and Siniscalco, M. 1977. Radioimmune assay for Xg(a) surface antigen at the individual red cell level. Biochem. Biophys. Res. Commun 78:655.
20. Chirgwin, J. M, Przybyla, A. E., MacDonald, R J, and Rutter, W J. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonudease. Biochemistry 18:5494.
21. Leonard, W. J, Depper, J. M., Crabtree, G. R., Rudikoff, S., Pumphrey, J., Robb, R. J., Kronke, M, Svetlik, P B., Peffer, N J, Waldmann, T A, and Greene, W. C. 1984. Molecular cloning and expression of cDNAs for the human lnterleukin-2 receptor. Nature 311 626.
22. Wang, H.-M. and Smith, K A. 1987. The Interleukin 2 receptor: functional consequences of its bimolecular structure. J Exp Med 166 1055.
23. Lowenthal, J. W. and Greene, W. C. 1987. Contrasting Interleukin 2 binding properties of the (p55) and (p70) protein subunits of the human high-affinity Interleukin 2 receptor. J Exp Med 166:1156.
24. Van Wouwe, J. P., Goosens, J. G., and Beverley, P C. L. 1984. Human T lymphocyte activation by monoclonal antibodies, OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism. J. Immunol 133 129.
25. Tsoukas, C D, Landgraf, B., Bentin, J., Valentine, M., Lotz, M., Vaughan, J. H., and Carson, D. A. 1985. Activation of resting T lymphocytes by anti-CD3 (T3) antibodies in the absence of monocytes. J. Immunol. 135:1710.
26. Nagel, J E, Chopra, R. K. Chrest, F. J. McCoy, M. T. Schneider, E L, Holbrook N J, and Adler, W H. 1988. Decreased proliferation, Interleukin 2 synthesis, and Interleukin 2 receptor expression are accompanied by decreased mRNA expression in phytohemagglutinin-stimulated ceSs from elderly donors. J. Clin. Invest. 81:1096.
27. O’Flynn, K, Krertsky, A. M., Beverley, P. C. L., Burakoff, S. J., and Lirtch, D. C. 1985. Phytohemagglutinin activation of T cells through the sheep red blood cell receptor. Nature 313:686.
28. Sanders, M. E., Makgoba, M. W., and Shaw, S. 1988. Human naive and memory T cells: reinterpretation of hetper-inducer and suppressor-mducer subsets. Immunol. Today 9:195.
29. Sharon, M., Siegel, J. P, Tosato, G., Yodoi, J., Gerrard, T. L., and Leonard, W. J. 1988. The human Interleukin 2 receptor chain (p70). Direct identification, partial purification, and patterns of expression on peripheral blood mononuclear cells. J. Exp. Med. 167 1265.
30. Herrmann, T and Diamamtstein, T. 1988. The human intermediate affinity Interleukin 2 receptor consists of 2 distinct, partially homologous glycoproteins. Eur. J Immunol 181:1051.
31. Tsudo, M, Kitamura, F, and Miyasaka, M. 1989. Characterization of the interleukin 2 receptor chain using three distinct monoclonal antibodies. Proc Natl. Acad. Sci. USA 86:1982.
32. Takeshita, T, Goto.Y., Tada, K, Nagata, K., Asao, H., and Sugamura, K. 1989. Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor. J. Exp Med 169:1323.
33. Nakamura, Y, Inamoto, T, Sugie.K., Masutam, H, Shindo, T, Tagaya, Y, Yamauchi, A. Ozawa, K., and Yodoi, J. 1989. Mitogerucrty and down-regulation of high affinity interleukin 2 receptor by YTA-1 and YTA-2 monoclonal antibodies that recognize 75 kDa molecules on human large granular lymphocytes. Proc. Natl. Acad Sci. USA 861:318.
34. Woda, B. A and Feldman, J. D. 1979. Density of surface immunoglobulin and capping on rat B lymphocytes. I Changes with aging. J. Exp. Med 149:416.
35. Woda, B. A., Yguerabide, J., and Feldman, J. D. 1979. Mobility and density of AgB, la, and Fc receptors on the surface of lymphocytes from young and old rats. J. Immunol. 123:2161.
36. Naeim, F and Walford, R. L. 1980. Disturance of redistribution of surface membrane receptors on peripheral mononuclear cells of patients with Down’s syndrome. J. Geront. 35:650.